Home

Latest News

12345678910
BeautyHealth (NASDAQ:SKIN) Reports Bullish Q1
Skincare company BeautyHealth (NASDAQ:SKIN) announced better-than-expected revenue in Q1 CY2025, but sales fell by 14.5% year on year to $69.6 million. On the other hand, next quarter’s revenue guidance of $73.5 million was less impressive, coming in 2.9% below analysts’ estimates. Its GAAP loss of $0.08 per share was 37.6% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
1-800-FLOWERS (NASDAQ:FLWS) Reports Sales Below Analyst Estimates In Q1 Earnings, Stock Drops
E-commerce florist and gift retailer 1-800-FLOWERS (NASDAQ:FLWS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 12.6% year on year to $331.5 million. Its non-GAAP loss of $0.71 per share was significantly below analysts’ consensus estimates.
Via StockStory · May 8, 2025
USA Economy To Pick Up Second Half Of 2025talkmarkets.com
Trump has lowered the U.S. dollar, this has allowed China to print.
Via Talk Markets · May 8, 2025
Toast Stock Rallies After Q1 Results, Signs Agreement With Topgolfbenzinga.com
Topgolf releases its first-quarter results and announces a new agreement with Topgolf.
Via Benzinga · May 8, 2025
P/E Ratio Insights for CPI Cardbenzinga.com
Via Benzinga · May 8, 2025
U.S. Dollar Dead Cat Bouncetalkmarkets.com
U.S. dollar rally has weak bounce and Fed stands pat.
Via Talk Markets · May 8, 2025
EVgo Is Well-Positioned For Robust Revenue Growth: Analystbenzinga.com
J.P. Morgan analyst Bill Peterson maintained an Overweight rating on EVgo Inc (NASDAQ:EVGO) with a $5 price target, citing strong revenue driven by the eXtend business and reaffirmed financial guidance. The DOE loan remains on track, easing investor concerns.
Via Benzinga · May 8, 2025
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98 billion at the midpoint came in 3.1% above analysts’ estimates. Its GAAP loss of $0.50 per share was 21.4% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Skillz (NYSE:SKLZ) Delivers Strong Q1 Numbers
Mobile game developer Skillz (NYSE:SKLZ) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 11.2% year on year to $22.41 million. Its GAAP loss of $0.92 per share was 16.4% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Trex’s (NYSE:TREX) Q1 Sales Top Estimates
Composite decking and railing products manufacturer Trex Company (NYSE:TREX) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 9% year on year to $340 million. Its GAAP profit of $0.56 per share was 4.1% below analysts’ consensus estimates.
Via StockStory · May 8, 2025
One of the Largest Teacher Pension Funds in the U.S. Sold Nvidia, Tesla, and Apple and Piled Into a Popular Pharmaceutical Stock Up 395% Over the Last 5 Yearsfool.com
Via The Motley Fool · May 8, 2025
Unpacking The High Stakes US-China AI Energy Racetalkmarkets.com
While the U.S. has a slim lead in AI, China has the edge when it comes to energy – and the U.S. will need to play catchup (and fast).
Via Talk Markets · May 8, 2025
Hub Group (NASDAQ:HUBG) Reports Sales Below Analyst Estimates In Q1 Earnings
Logistics solutions provider Hub Group (NASDAQ:HUBG) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 8.4% year on year to $915.2 million. The company’s full-year revenue guidance of $3.8 billion at the midpoint came in 5.6% below analysts’ estimates. Its GAAP profit of $0.44 per share was 3% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 Expectations
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.49 per share was 2.8% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
10x Genomics’s (NASDAQ:TXG) Q1: Strong Sales But Quarterly Revenue Guidance Significantly Misses Expectations
Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s revenue guidance of $140 million was less impressive, coming in 3.6% below analysts’ estimates. Its GAAP loss of $0.28 per share was 40.6% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Where Generation Bio Stands With Analystsbenzinga.com
Via Benzinga · May 8, 2025
The Analyst Verdict: MarketAxess Holdings In The Eyes Of 10 Expertsbenzinga.com
Via Benzinga · May 8, 2025
Assessing Ares Management: Insights From 11 Financial Analystsbenzinga.com
Via Benzinga · May 8, 2025
CDW Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)benzinga.com
Via Benzinga · May 8, 2025
Expert Outlook: Pediatrix Medical Group Through The Eyes Of 4 Analystsbenzinga.com
Via Benzinga · May 8, 2025
Here's How Much $100 Invested In Martin Marietta Materials 10 Years Ago Would Be Worth Todaybenzinga.com
Via Benzinga · May 8, 2025
Analyst Expectations For Remitly Global's Futurebenzinga.com
Via Benzinga · May 8, 2025
Bitcoin Miner CleanSpark Misses Q1 Earnings Estimates, Company On Track To Reach 50 EH/s Target In June, Shares Slidebenzinga.com
Bitcoin miner CleanSpark reportes first-quarter financial results after the market close on Thursday. Here's an overview of the report.
Via Benzinga · May 8, 2025
Stocks And Precious Metals Charts - Ignoring Geopolitical And Economic Riskscontent/com
The Dollar rallied back to the top of the 100 handle. VIX is now at the level where we will start looking for a correction.
Via Talk Markets · May 8, 2025
ICU Medical (NASDAQ:ICUI) Delivers Impressive Q1
Medical device company ICU Medical (NASDAQ:ICUI) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 6.7% year on year to $604.7 million. Its non-GAAP profit of $1.72 per share was 34.4% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Xponential Fitness (NYSE:XPOF) Surprises With Q1 Sales But Stock Drops
Boutique fitness studio franchisor Xponential Fitness (NYSE:XPOF) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 3.3% year on year to $76.88 million. The company expects the full year’s revenue to be around $320 million, close to analysts’ estimates. Its non-GAAP loss of $0.20 per share was significantly below analysts’ consensus estimates.
Via StockStory · May 8, 2025
Pursuit (NYSE:PRSU) Misses Q1 Sales Targets
Experiential tourism company Pursuit Attractions and Hospitality (NYSE:PRSU) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 86.3% year on year to $37.58 million. Its non-GAAP loss of $0.96 per share was 31.5% below analysts’ consensus estimates.
Via StockStory · May 8, 2025
HubSpot Beats Estimates, Raises Guidance, Shares Sink: The Detailsbenzinga.com
HubSpot beats analyst estimates in the first quarter and raised guidance. Here are the key highlights.
Via Benzinga · May 8, 2025
Alarm.com (NASDAQ:ALRM) Beats Q1 Sales Targets
Home security and automation software provider Alarm.com (NASDAQ:ALRM) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 7% year on year to $238.8 million. The company expects the full year’s revenue to be around $983.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.54 per share was 13.8% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Illumina’s (NASDAQ:ILMN) Q1 Sales Top Estimates
Genomics company Illumina (NASDAQ:ILMN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 1.4% year on year to $1.04 billion. Its non-GAAP profit of $0.97 per share was 3.2% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Arlo Technologies’s (NYSE:ARLO) Q1 Sales Top Estimates
Smart security company Arlo (NYSE:ARLO) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 4.1% year on year to $119.1 million. Its non-GAAP profit of $0.15 per share was 28.2% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Monster (NASDAQ:MNST) Misses Q1 Revenue Estimates
Energy drink company Monster Beverage (NASDAQ:MNST) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 2.3% year on year to $1.85 billion. Its non-GAAP profit of $0.47 per share was 2.2% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Karat Packaging (NASDAQ:KRT) Posts Better-Than-Expected Sales In Q1, Provides Encouraging Quarterly Revenue Guidance
Foodservice packaging supplier Karat Packaging (NASDAQ:KRT) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 8.4% year on year to $103.6 million. Guidance for next quarter’s revenue was better than expected at $123.9 million at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.30 per share was 5.3% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
Here's How Much You Would Have Made Owning CrowdStrike Holdings Stock In The Last 5 Yearsbenzinga.com
Via Benzinga · May 8, 2025
Why Gray Media Stock Skyrocketed Almost 19% Higher on Thursdayfool.com
Via The Motley Fool · May 8, 2025
McKesson (NYSE:MCK) Misses Q1 Revenue Estimates
Healthcare distributor and services company McKesson (NYSE:MCK) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 18.9% year on year to $90.82 billion. Its non-GAAP profit of $10.12 per share was 3% above analysts’ consensus estimates.
Via StockStory · May 8, 2025
These 2 Stocks Could Benefit After The U.S. Lifts Tariffs On UK Steel And Aluminumtalkmarkets.com
Tata Steel and Rio Tinto stand to benefit from the US-UK trade deal.
Via Talk Markets · May 8, 2025
Compass (NYSE:COMP) Misses Q1 Sales Targets
Real estate technology company Compass (NYSE:COMP) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 28.7% year on year to $1.36 billion. Next quarter’s revenue guidance of $2.08 billion underwhelmed, coming in 1.5% below analysts’ estimates. Its non-GAAP loss of $0.09 per share was significantly below analysts’ consensus estimates.
Via StockStory · May 8, 2025
Serve Robotics Stock Slides On Mixed Q1 Earnings, Company Expects To Deploy 2,000 Robots By Year-Endbenzinga.com
Serve Robotics reports first-quarter revenue of $440,460, missing analyst estimates of $486,670, according to Benzinga Pro.
Via Benzinga · May 8, 2025
Evolent Health (NYSE:EVH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations
Healthcare solutions company Evolent Health (NYSE:EVH) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 24.4% year on year to $483.6 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $455 million was less impressive, coming in 9.4% below expectations. Its non-GAAP profit of $0.06 per share was 37.7% below analysts’ consensus estimates.
Via StockStory · May 8, 2025
The RealReal (NASDAQ:REAL) Reports Q1 In Line With Expectations But Stock Drops 10.5%
Secondhand luxury marketplace The RealReal (NASDAQ: REAL) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 11.3% year on year to $160 million. On the other hand, next quarter’s revenue guidance of $159 million was less impressive, coming in 0.8% below analysts’ estimates. Its non-GAAP loss of $0.08 per share was in line with analysts’ consensus estimates.
Via StockStory · May 8, 2025
Stocks Surge As Trade Optimism Picks Upcontent/com
Trade war tailwinds were blowing for stocks today, with the Dow and Nasdaq both adding triple digits, the tech-heavy latter making a run at 18,000.
Via Talk Markets · May 8, 2025
Microchip Technology (NASDAQ:MCHP) Q1: Beats On Revenue, Stock Soars
Analog chipmaker Microchip Technology (NASDAQ:MCHP) announced better-than-expected revenue in Q1 CY2025, but sales fell by 26.8% year on year to $970.5 million. On top of that, next quarter’s revenue guidance ($1.05 billion at the midpoint) was surprisingly good and 5.1% above what analysts were expecting. Its non-GAAP profit of $0.11 per share was in line with analysts’ consensus estimates.
Via StockStory · May 8, 2025
Healthy body, healthy brain: Tips to optimize your brain health
(BPT) - By 2030, more than 20% of the U.S. population - about 71 million Americans - will be over the age of 65. With age, many of us may notice changes in cognition - things like misplacing our keys or forgetting a neighbor's name. While we expect our bodies to change with age and aren't alarmed when they do, many people assume the worst when their memory or cognition changes. It's important to understand that our brains age just like our bodies.
Via Brandpoint · May 8, 2025
Market Talk - Thursday, May 8talkmarkets.com
Russell 2000 advanced 36.76 points or 1.85% to 2,026.42.
Via Talk Markets · May 8, 2025
Globalstar (NASDAQ:GSAT) Misses Q1 Revenue Estimates
Satellite communications provider Globalstar (NASDAQ:GSAT) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 6.3% year on year to $60.03 million. On the other hand, the company’s full-year revenue guidance of $272.5 million at the midpoint came in 3.1% above analysts’ estimates. Its GAAP loss of $0.16 per share was significantly below analysts’ consensus estimates.
Via StockStory · May 8, 2025
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Todaybenzinga.com
Via Benzinga · May 8, 2025
Sweetgreen’s (NYSE:SG) Q1 Sales Beat Estimates But Stock Drops
Casual salad chain Sweetgreen (NYSE:SG) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 5.4% year on year to $166.3 million. On the other hand, the company’s full-year revenue guidance of $750 million at the midpoint came in 1.8% below analysts’ estimates. Its GAAP loss of $0.21 per share was in line with analysts’ consensus estimates.
Via StockStory · May 8, 2025
Olo’s (NYSE:OLO) Q1: Beats On Revenue, Full-Year Outlook Slightly Exceeds Expectations
Restaurant software company (NYSE:OLO) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 21.3% year on year to $80.68 million. Guidance for next quarter’s revenue was better than expected at $82.25 million at the midpoint, 0.5% above analysts’ estimates. Its non-GAAP profit of $0.07 per share was in line with analysts’ consensus estimates.
Via StockStory · May 8, 2025
Expedia Stock Trades Down On Q1 Revenue Miss: 'Weaker Than Expected Demand In The US'benzinga.com
Expedia stock is falling Thursday after Q1 results. Management commentary on domestic travel could be the reason. Here's what they said.
Via Benzinga · May 8, 2025